Drupal.behaviors.print = function(context) {window.print();window.close();}>
Myriad Publishes Data on HRD Test to Detect Response to Platinum-Based Therapy, PARP Inhibitors
October 17, 2012
Myriad Publishes Data on HRD Test to Detect Response to Platinum-Based Therapy, PARP Inhibitors
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Federal Court Rules that Myriad's BRCA Patents are Invalid; Deems 'Isolated DNA' Unpatentable
March 30, 2010 / GenomeWeb Daily News
Reporting 27 Percent Q3 Jump, Myriad Outlines Three-Pronged Plan for Diversifying Revenue Base
May 2, 2012 / Pharmacogenomics Reporter
Posting 11 Percent Revenue Growth in FY2011, Myriad Focuses on Growing MDx Pipeline
August 10, 2011 / Pharmacogenomics Reporter
SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter
GenomeWeb Feature: Regardless of Gene Patent Challenges, Myriad Faces Shifting Competitive Landscape
April 17, 2013 / Pharmacogenomics Reporter